A CASE OF LONG-TERM OBSERVATION OF A CHILD WITH SANFILIPPO SYNDROME
##article.subject##:
Sanfilippo syndrome, mucopolysaccharidosis, children, neurocognitive disorders##article.abstract##
Mucopolysaccharidosis type III (Sanfilippo syndrome) is a rare multisystem disease caused by the accumulation of glycosaminoglycans (GAG) in cells of various organs, leading to impaired function, specific phentopic signs and progressive neurocognitive disorders. Polymorphism and non-specificity of clinical manifestations are a common cause of late diagnosis of MPS.
We present our own prolonged clinical observation of a type III MPS case in a patient who was under our supervision for 12 years. The diagnosis was established and confirmed at the age of three. The disease manifested itself by neuropsychiatric regression and systemic somatic manifestations. Motor deficits, cognitive impairments with the development of dementia and recurrent aspiration syndrome progressed in the dynamics of the child.
Библиографические ссылки
Benetó N, Vilageliu L, Grinberg D, Canals I. Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches. Int J Mol Sci. 2020; 21(21):7819. Published 2020 Oct 22. https://doi:10.3390/ijms21217819
Buchinskaya N.V., Chikova I.A., Isupova E.A., Kalashnikova O.V., Kostik M.M., Chasnyk V.G. Modern approaches to the treatment of mucopolysaccharidoses in children. Issues of modern pediatrics. 2014;13(3):35-43. https://doi.org/10.15690/vsp.v13i3.1026]
Zelei T, Csetneki K, Vokó Z, Siffel C. Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet J Rare Dis. 2018;13(1):53. Published 2018 Apr 10. https://doi:10.1186/s13023-018-0796-4
Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type A. J. Inherit. Metab. Dis. 2014;37(3):431–437.
Cross EM, Grant S, Jones S, Bigger BW, Wraith JE, Mahon LV, Lomax M, Hare DJ. An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type III. J. Neurodev. Disord. 2014; 6 (1): 46.
Kong W, Wu S, Zhang J, Lu C, Ding Y, Meng Y. Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism. 2021;34(10):1225-1235. https://doi.org/10.1515/jpem-2020-0742
Wagner VF, Northrup H. Mucopolysaccharidosis Type III. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; September 19, 2019.
Lavery C, Hendriksz CJ, Jones SA. Mortality in patients with Sanfilippo syndrome. Orphanet J Rare Dis. 2017;12(1):168. Published 2017 Oct 23. https://doi.org/10.1186/s13023-017-0717-y
Saryeva O.P., Kulida L.V., Protsenko E.V., Malysheva M.V. Cardiomyopathy in children – clinical, genetic and morphological aspects // Russian Medical and Biological Bulletin. academician I.P. Pavlov. 2020. №1. C. 99-110. https://doi.org/10.23888/PAVLOVJ202028199-110
Ruijter GJ, Valstar MJ, van de Kamp JM идр. Clinical and genetic spectrum of Sanfilippo type C disease (MPS III) in the Netherlands. Mol Genet Metab. 2008;93(2):104-111. https://doi.org/10.1016/j.ymgme.2007.09.011
A Tylki-Szymańska, B Czartoryska, D Górska, E Piesiewicz-Grzonkowska. Type III D mucopolysaccharidosis (Sanfilippo D): clinical course and symptoms ActaPaediatrJpn. 1998 Oct;40(5):492-4. doi: 10.1111/j.1442-200x.1998.tb01977.x
